therapeutic mechanisms

Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response

mycolabadmin

Researchers studied how LSD and psilocybin work in real-world therapy settings in Switzerland. They found that these compounds effectively reduced depression symptoms in patients who hadn’t responded to other treatments. Surprisingly, the feeling of relaxation during the session was more important for improvement than having intense mystical experiences. The therapy was generally safe, with side effects that resolved quickly.

Recent advances in natural polysaccharides for type 2 diabetes management: sources, structural characteristics, and mechanistic insights

mycolabadmin

Natural polysaccharides from plants, mushrooms, and seaweed show promise as treatments for type 2 diabetes. These complex sugar molecules work through multiple mechanisms including improving how the body uses insulin, reducing inflammation and oxidative stress, and promoting beneficial gut bacteria. The effectiveness of these polysaccharides depends on their specific chemical structure, particularly their molecular weight and how their sugar units are linked together.

Long-COVID symptoms improved after MDMA and psilocybin therapy: A case report

mycolabadmin

A 41-year-old woman with Long-COVID experienced severe symptoms including fatigue, depression, anxiety, headaches, and brain fog that didn’t improve with traditional treatments. She decided to try psilocybin mushrooms and MDMA with guidance from a therapist. After multiple dosing sessions over several months, she reported roughly 80-90% improvement in her symptoms and was able to return to work and resume her studies. While this single case is promising, more research is needed to determine whether these psychedelics are truly safe and effective for Long-COVID.

Down the rabbit hole – the psychological and neural mechanisms of psychedelic compounds and their use in treating mental health and medical conditions

mycolabadmin

Psychedelic compounds like psilocybin and LSD are showing significant promise for treating various mental health conditions including depression, anxiety, and PTSD. These substances appear to work through multiple mechanisms, including inducing profound mystical experiences and increasing neuroplasticity in the brain. Research indicates that environmental and contextual factors significantly influence how effective these treatments are, and even virtual reality experiences mimicking psychedelic effects show therapeutic benefits. The field is moving toward responsible, evidence-based clinical applications of psychedelics in psychiatry.

Therapeutic Effects of Natural Products on Liver Cancer and Their Potential Mechanisms

mycolabadmin

This review examines how natural products from plants, fungi, and marine organisms can help treat liver cancer more safely and effectively than current drugs. These natural compounds work through multiple pathways such as triggering cancer cell death, stopping cell growth, and boosting the immune system. The research found that seven categories of natural products show promise, with sources ranging from ginseng and turmeric to mushrooms and seaweed, offering potential new treatment options that could reduce side effects and drug resistance.

Catalyst for change: Psilocybin’s antidepressant mechanisms—A systematic review

mycolabadmin

This research review examines how psilocybin, a compound from certain mushrooms, may help treat depression by creating changes in both brain function and psychological experience. Within supportive therapeutic settings, psilocybin appears to increase cognitive flexibility, help people better process emotions, and restore a sense of connection to themselves, others, and the world. The antidepressant benefits seem to work through a combination of direct brain changes and psychotherapeutic factors, rather than through pure pharmacological action alone.

Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome

mycolabadmin

This study examined whether the psychological experiences people have while taking ketamine or psilocybin—such as feeling disconnected or having spiritual insights—are actually responsible for their mental health improvements. Researchers analyzed 23 studies and found that these subjective experiences explain about 10% of ketamine’s benefits and 24% of psilocybin’s benefits. Psilocybin’s effects appear more connected to therapeutic outcomes than ketamine’s, and both drugs showed stronger connections between subjective effects and treatment success in substance use disorder compared to depression.

Striking long-term beneficial effects of single dose psilocybin and psychedelic mushroom extract in the SAPAP3 rodent model of OCD-like excessive self-grooming

mycolabadmin

Researchers tested whether psilocybin (the active compound in magic mushrooms) could treat obsessive-compulsive disorder using genetically modified mice that exhibit excessive grooming similar to OCD in humans. A single dose of psilocybin or psychedelic mushroom extract significantly reduced the excessive grooming behavior and anxiety in these mice, with benefits lasting up to six weeks. These findings suggest psilocybin may be a promising new treatment for OCD in humans, offering longer-lasting effects from a single dose compared to current medications.

Research Topic: therapeutic mechanisms